Progressive supranuclear palsy atypical

Also Known As:

Atypical PSP; Parkinson-Dementia Syndrome; Steele-Richardson-Olszewski Syndrome, Atypical; Supranuclear Palsy, Progressive Atypical; Supranuclear Palsy, Progressive, 1, Atypical

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Nervous System Diseases: 14178
Eye Diseases: 3522
- Ocular Motility Disorders: 514
  - Ophthalmoplegia: 867
    - Progressive Supranuclear Palsy: 1232
      - Progressive supranuclear palsy atypical: 5
Signs and Symptoms Pathological Conditions
- Signs and Symptoms
  - Neurologic Manifestations: 7102
    - Paralysis: 14164
      - Ophthalmoplegia: 867
        Progressive Supranuclear Palsy: 1232
        Progressive supranuclear palsy atypical: 5

Related Diseases

1.	Cognitive Dysfunction
2.	Amyloid Plaque
3.	Parkinson Disease (Parkinson's Disease)
4.	Infarction (Infarctions)
5.	Atrophy

Experts

1.	Freund, Hans-Joachim: 2 articles (07/2010 - 06/2009)
2.	Kuhn, Jens: 2 articles (07/2010 - 06/2009)
3.	Lenartz, Doris: 2 articles (07/2010 - 06/2009)
4.	Sturm, Volker: 2 articles (07/2010 - 06/2009)
5.	Papagno, Costanza: 1 article (02/2018)
6.	Trojano, Luigi: 1 article (02/2018)
7.	Barnikol, Thomas T: 1 article (07/2010)
8.	Barnikol, Utako B: 1 article (07/2010)
9.	Pawelczyk, Norbert B A: 1 article (07/2010)
10.	Tass, Peter A: 1 article (07/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Progressive supranuclear palsy atypical:

1.	Cholinergic Agents (Cholinergics)IBA 02/01/2018 - "Part of these defects is ascribed to a dopamine-dependent dysfunction of fronto-striatal pathways, but there is a considerable heterogeneity in the cognitive impairments as well as a suggestion of the role of other neurotransmitter systems, such as the cholinergic one, mainly responsible for Parkinson-dementia syndrome. "
2.	Neurotransmitter Agents (Neurotransmitter)IBA 02/01/2018 - "Part of these defects is ascribed to a dopamine-dependent dysfunction of fronto-striatal pathways, but there is a considerable heterogeneity in the cognitive impairments as well as a suggestion of the role of other neurotransmitter systems, such as the cholinergic one, mainly responsible for Parkinson-dementia syndrome. "
3.	Levodopa (L Dopa)FDA LinkGeneric 05/01/2002 - "The clinically atypical PSP group contains a number of different clinical syndromes, including an L-dopa unresponsive bradykinetic syndrome and a clinical syndrome closely resembling idiopathic Parkinson's disease. "
4.	Dopamine (Intropin)FDA LinkGeneric 02/01/2018 - "Part of these defects is ascribed to a dopamine-dependent dysfunction of fronto-striatal pathways, but there is a considerable heterogeneity in the cognitive impairments as well as a suggestion of the role of other neurotransmitter systems, such as the cholinergic one, mainly responsible for Parkinson-dementia syndrome. "
5.	Prion ProteinsIBA 11/01/1994 - "Criteria excluding the diagnosis of typical and atypical PSP are large or numerous infarcts, marked diffuse or focal atrophy, Lewy bodies, changes diagnostic of Alzheimer's disease, oligodendroglial argyrophilic inclusions, Pick bodies, diffuse spongiosis, and prion protein-positive amyloid plaques. "

Therapies and Procedures

1.	Deep Brain Stimulation 06/01/2009 - "Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation." 07/30/2010 - "Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome."